April 24, 2007
LOS ANGELES, April 24, 2007 – Kythera Biopharmaceuticals, Inc. ("Kythera") announced today the appointment of Jeff Webster as Vice President, Product Development and Operations. Webster will be for responsible for Kythera’s Product Teams (PTs), which guide product development from late preclinical through commercialization, as well as Manufacturing and Quality for clinical and commercial supply.
Webster, a 19 year Amgen veteran, has held positions of increasing responsibility in process development, engineering, investor relations, European marketing, product development, portfolio management, corporate development and strategy, and operations. As the product development team leader for NEUPOGEN®/NEULASTA®1, Webster oversaw multiple regulatory filings in US, Europe, Canada and Australia and led efforts to expand the clinical and commercial footprint of this important medicine. In his most recent position as Vice President, Operations Planning at Amgen, Webster led an 85-person group in product development, project management, training and development, and strategy functions within the Operations function.
Webster holds a Masters in Business Administration from San Jose State University and a Bachelor of Science in Chemical Engineering from University of California, Berkeley.
“The addition of Jeff to Kythera’s senior management team represents a significant step forward for the company,” said Leonard. “Jeff is a seasoned biotechnology executive whose broad experience and leadership skills will have a immediate impact on our ability to develop and commercialize great products.”
Kythera has ongoing clinical programs for ATX-101 in the US and Europe and for ATX-201 in Europe. Additionally, Kythera has active research programs and product candidates in photoaging, dermal contouring and topical neuromodulation.
1 NEUPOGEN®/NEULASTA® are registered trademarks of Amgen Inc.